ADC Therapeutics S.A.

Business Description

ADC Therapeutics is a Swiss-based biopharmaceutical company focused on developing targeted cancer treatments using antibody drug conjugate technology. Its lead product, ZYNLONTA, has received regulatory approval in the United States, Europe, and China for treating a specific type of aggressive blood cancer that has returned or stopped responding to prior treatment. The company is working to expand ZYNLONTA's use into earlier stages of disease and additional cancer types, both alone and in combination with other therapies. It also has a broader pipeline of earlier-stage compounds targeting several cancer-related proteins across multiple tumor types.